- Home
- FBIOP vs CCIA Comparison
FBIOP vs CCIA Comparison
Compare FBIOP & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- CCIA
- Stock Information
- Founded
- FBIOP N/A
- CCIA N/A
- Country
- FBIOP United States
- CCIA
- Employees
- FBIOP 101
- CCIA N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- CCIA
- Sector
- FBIOP Health Care
- CCIA
- Exchange
- FBIOP Nasdaq
- CCIA Nasdaq
- Market Cap
- FBIOP N/A
- CCIA N/A
- IPO Year
- FBIOP N/A
- CCIA 2023
- Fundamental
- Price
- FBIOP $6.93
- CCIA $25.70
- Analyst Decision
- FBIOP
- CCIA
- Analyst Count
- FBIOP 0
- CCIA 0
- Target Price
- FBIOP N/A
- CCIA N/A
- AVG Volume (30 Days)
- FBIOP N/A
- CCIA N/A
- Earning Date
- FBIOP N/A
- CCIA N/A
- Dividend Yield
- FBIOP N/A
- CCIA N/A
- EPS Growth
- FBIOP N/A
- CCIA N/A
- EPS
- FBIOP N/A
- CCIA N/A
- Revenue
- FBIOP N/A
- CCIA N/A
- Revenue This Year
- FBIOP N/A
- CCIA N/A
- Revenue Next Year
- FBIOP N/A
- CCIA N/A
- P/E Ratio
- FBIOP N/A
- CCIA N/A
- Revenue Growth
- FBIOP N/A
- CCIA N/A
- 52 Week Low
- FBIOP N/A
- CCIA N/A
- 52 Week High
- FBIOP N/A
- CCIA N/A
- Technical
- Relative Strength Index (RSI)
- FBIOP 36.60
- CCIA 49.47
- Support Level
- FBIOP $6.56
- CCIA $25.69
- Resistance Level
- FBIOP $7.23
- CCIA $25.78
- Average True Range (ATR)
- FBIOP 0.52
- CCIA 0.09
- MACD
- FBIOP -0.09
- CCIA -0.01
- Stochastic Oscillator
- FBIOP 21.08
- CCIA 67.60
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.